Not Signed In -
Thalidomide |
Thalomid |
This article is about the drug. For the musical, see Thalidomide!! A Musical. Thalidomide Systematic (IUPAC) name 2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione Identifiers CAS number 50-35-1 ATC code ? PubChem ? Chemical data Formula C13H10N2O4 Mol. weight 258.2 Pharmacokinetic data Bioavailability ? Metabolism Exact metabolic pathway currently not known in humans, but the safer version (R)-Thalidomide is converted to (S)-Thalidomid ...
Wikipedia - [full article]
Thalidomide Clinical Trials
- Thal/Dex (Thalidomide and Dexamethasone) vs. Dd-T (Doxil, Dexamethasone and Thalidomide) in Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00097981 - Active, not recruiting
Multiple Myeloma
- Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
ClinicalTrials.gov Identifier: NCT00075023 - Recruiting
- Using the Drug Thalidomide to Stimulate T Cells in HIV Positive Patients
ClinicalTrials.gov Identifier: NCT00053430 - Active, not recruiting
HIV Infections
- Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
ClinicalTrials.gov Identifier: NCT00083382 - Active, not recruiting
Multiple Myeloma
- Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
ClinicalTrials.gov Identifier: NCT00006198 - Active, not recruiting
Liver Cancer
- Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
ClinicalTrials.gov Identifier: NCT00049296 - Active, not recruiting
Cancer
- Thalidomide in Treating Patients With Myelofibrosis
ClinicalTrials.gov Identifier: NCT00015821 - Active, not recruiting
Agnogenic Myeloid Metaplasia
- Thalidomide and Dacarbazine for Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00006200 - Active, not recruiting
Melanoma
- Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00052416 - Active, not recruiting
adult non-Hodgkin's lymphoma
- Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00057564 - Active, not recruiting
Multiple Myeloma
- Thalidomide/Dexamethasone Vs MP for Induction Therapy and Thalidomide/Intron A Vs Intron A for Maintenance Therapy
ClinicalTrials.gov Identifier: NCT00205751 - Recruiting
Multiple Myeloma
- Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
ClinicalTrials.gov Identifier: NCT00033254 - Active, not recruiting
brain metastases
- Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
ClinicalTrials.gov Identifier: NCT00025220 - Active, not recruiting
recurrent uterine sarcoma; uterine leiomyosarcoma
- Phase II Trial of Peginterferon alpha-2b and Thalidomide in Adults with Recurrent Gliomas
ClinicalTrials.gov Identifier: NCT00047879 - Recruiting
Glioma
- Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
ClinicalTrials.gov Identifier: NCT00016224 - Active, not recruiting
recurrent ovarian epithelial cancer
- Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00104988 - Active, not recruiting
Stage IV Melanoma
- Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
ClinicalTrials.gov Identifier: NCT00005815 - Active, not recruiting
intraocular melanoma; Melanoma
- Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
ClinicalTrials.gov Identifier: NCT00072345 - Active, not recruiting
intraocular melanoma; Melanoma
- Study of Combination PS-341 and Thalidomide in Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00083460 - Active, not recruiting
Multiple Myeloma
- Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124813 - Recruiting
Multiple Myeloma
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00049374 - Active, not recruiting
refractory plasma cell neoplasm
- Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
ClinicalTrials.gov Identifier: NCT00089609 - Recruiting
Prostatic Neoplasms
- Estramustine, Docetaxel, and Thalidomide to Treat Advanced Prostate Cancer
ClinicalTrials.gov Identifier: NCT00078650 - Recruiting
Prostatic Neoplasms
- Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
ClinicalTrials.gov Identifier: NCT00004635 - Recruiting
Prostate Cancer
- Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00027638 - Active, not recruiting
gastrointestinal carcinoid tumor; Islet Cell Carcinoma; pulmonary carcinoid tumor
- Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00006226 - Active, not recruiting
refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
- Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
ClinicalTrials.gov Identifier: NCT00033709 - Active, not recruiting
adult soft tissue sarcoma; uterine leiomyosarcoma; uterine sarcoma
- Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00053300 - Active, not recruiting
extensive stage small cell lung cancer
- Thalidomide and Rituximab in Waldenstrom''s Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00142116 - Active, not recruiting
Waldenstrom''s Macroglobulinemia; Lymphoplasmacytic lymphoma
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
ClinicalTrials.gov Identifier: NCT00046826 - Active, not recruiting
adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer
- Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer
ClinicalTrials.gov Identifier: NCT00082693 - Active, not recruiting
adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
- Thalidomide and Temozolomide in Treating Young Patients With Relapsed or Progressive Brain Tumors or Recurrent Neuroblastoma
ClinicalTrials.gov Identifier: NCT00098865 - Active, not recruiting
childhood brain tumor; childhood meningioma; childhood spinal cord tumors; Neuroblastoma
- Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
ClinicalTrials.gov Identifier: NCT00047294 - Active, not recruiting
Mixed Gliomas; adult glioblastoma; adult giant cell glioblastoma; adult gliosarcoma
- Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
ClinicalTrials.gov Identifier: NCT00039468 - Active, not recruiting
adult glioblastoma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma
- Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
ClinicalTrials.gov Identifier: NCT00155272 - Recruiting
Hepatocellular Carcinoma
- Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
ClinicalTrials.gov Identifier: NCT00089167 - Active, not recruiting
primary systemic amyloidosis
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00098475 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- PEG-Interferon alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
ClinicalTrials.gov Identifier: NCT00090870 - Active, not recruiting
Stage IV Renal Cell Cancer
- Preoperative Thalidomide With Radiation Therapy for Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy, Doxorubicin, Ifosfamide, and Dacarbazine for Patients with High or Intermediate Grade Primary Soft Tissue Sarcom
ClinicalTrials.gov Identifier: NCT00089544 - Active, not recruiting
stage I adult soft tissue sarcoma; stage II adult soft tissue sarcoma; stage III adult soft tissue sarcoma; recurrent adult soft tissue sarcoma
- Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00019747 - Active, not recruiting
stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer
- Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
ClinicalTrials.gov Identifier: NCT00047281 - Active, not recruiting
adult anaplastic astrocytoma; adult anaplastic oligodendroglioma; adult brain tumor; adult glioblastoma; Mixed Gliomas
- Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
ClinicalTrials.gov Identifier: NCT00025506 - Recruiting
recurrent uterine sarcoma; uterine carcinosarcoma
- Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
ClinicalTrials.gov Identifier: NCT00014443 - Active, not recruiting
recurrent adult brain tumor; adult glioblastoma; adult anaplastic astrocytoma; adult giant cell glioblastoma; adult gliosarcoma
- Interferon alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
ClinicalTrials.gov Identifier: NCT00005966 - Active, not recruiting
stage III renal cell cancer; Stage IV Renal Cell Cancer
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00028886 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma
- Thalidomide in Treating Patients With Thyroid Cancer
ClinicalTrials.gov Identifier: NCT00026533 - Active, not recruiting
stage IV papillary thyroid cancer; stage IV follicular thyroid cancer; medullary thyroid cancer; recurrent thyroid cancer; insular thyroid cancer
- Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00061919 - Active, not recruiting
extensive stage small cell lung cancer; limited stage small cell lung cancer
- IFM 99-02 Thalidomide in Myeloma
ClinicalTrials.gov Identifier: NCT00222053 - Active, not recruiting
Multiple Myeloma
- Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00040937 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
ClinicalTrials.gov Identifier: NCT00083005 - Active, not recruiting
Prostate Cancer
- Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
ClinicalTrials.gov Identifier: NCT00445900 - Active, not recruiting
Chronic Myeloproliferative Disorders; Secondary Myelofibrosis
- Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00015912 - Active, not recruiting
recurrent grade I follicular small cleaved cell lymphoma; recurrent grade II follicular mixed cell lymphoma
- Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
ClinicalTrials.gov Identifier: NCT00003894 - Active, not recruiting
Graft Versus Host Disease; unspecified childhood solid tumor, protocol specific; unspecified adult solid tumor, protocol specific
- Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00114192 - Active, not recruiting
recurrent non-small cell lung cancer; stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; ...
- Interferon alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
ClinicalTrials.gov Identifier: NCT00027664 - Recruiting
Stage IV Renal Cell Cancer
- Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
ClinicalTrials.gov Identifier: NCT00041080 - Active, not recruiting
stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; Fallopian Tube Cancer; ...
- SARCOTHAL. Thalidomide in Skin Sarcoidosis
ClinicalTrials.gov Identifier: NCT00305552 - Active, not recruiting
Sarcoidosis
- Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Treating Patients With Stage III Non-small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00004859 - Active, not recruiting
Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; large cell lung cancer; Non-small cell lung cancer; ...
- PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00238329 - Active, not recruiting
Intraocular Melanoma; Melanoma (Skin)
- Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00022581 - Recruiting
recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma; ...
- Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004088 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
ClinicalTrials.gov Identifier: NCT00112502 - Recruiting
adult giant cell glioblastoma; adult gliosarcoma; adult glioblastoma
- The Effects of Thalidomide on Symptom Clusters
ClinicalTrials.gov Identifier: NCT00379353 - Recruiting
Advanced Cancers
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00227682 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00193544 - Active, not recruiting
Multiple Myeloma
- Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00049673 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
ClinicalTrials.gov Identifier: NCT00026416 - Active, not recruiting
stage III adult soft tissue sarcoma; stage IVB adult soft tissue sarcoma; stage IVA adult soft tissue sarcoma; stage IIC adult soft tissue sarcoma; ...
- Thalidomide and Temozolomide or CPT-11 in Patients With Gliomas
ClinicalTrials.gov Identifier: NCT00412542 - Recruiting
Glioblastoma Multiforme; Glioma
- Docetaxel, Bevacizumab, Thalidomide, and Prednisone in Treating Patients With Metastatic Androgen-Independent Prostate Cancer
ClinicalTrials.gov Identifier: NCT00091364 - Recruiting
adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
- UARK 2003-33, Total Therapy III
ClinicalTrials.gov Identifier: NCT00081939 - Active, not recruiting
Multiple Myeloma
- The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
ClinicalTrials.gov Identifier: NCT00529633 - Recruiting
Hypoalbuminemia
- UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
ClinicalTrials.gov Identifier: NCT00574080 - Recruiting
Multiple Myeloma
- Total Therapy II
ClinicalTrials.gov Identifier: NCT00083551 - Active, not recruiting
Multiple Myeloma
- Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
ClinicalTrials.gov Identifier: NCT00450008 - Recruiting
Prostatic Neoplasms
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
ClinicalTrials.gov Identifier: NCT00258245 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
ClinicalTrials.gov Identifier: NCT00310076 - Active, not recruiting
Carcinoma of the Appendix; Colorectal Cancer
- Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00096018 - Recruiting
stage I chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; stage III chronic lymphocytic leukemia; ...
- DTPACE followed by Tandem Transplant with MEL 200 versus MEL/DTPACE Hybrid and DTPACE Consolidation
ClinicalTrials.gov Identifier: NCT00083915 - Active, not recruiting
Multiple Myeloma
- Leuprolide or Goserelin Plus Thalidomide Compared With Leuprolide or Goserelin Alone in Treating Patients With Nonmetastatic Prostate Cancer
ClinicalTrials.gov Identifier: NCT00020085 - Active, not recruiting
Prostate Cancer
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
ClinicalTrials.gov Identifier: NCT00527657 - Recruiting
Brain Neoplasms; Melanoma
- UFUR Plus Thalidomide for Advanced Hepatocelllular Carcinoma
ClinicalTrials.gov Identifier: NCT00519688 - Recruiting
Hepatocellular Carcinoma
- Rituximab and Combination Chemotherapy Followed By Thalidomide in Treating Patients With Previously Untreated Mantle Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00450801 - Recruiting
Lymphoma
- Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
ClinicalTrials.gov Identifier: NCT00004876 - Recruiting
stage I ovarian epithelial cancer; stage II ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112879 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- PEG-Interferon alfa-2b With or Without Thalidomide in Treating Patients With Recurrent High-Grade Gliomas
ClinicalTrials.gov Identifier: NCT00052650 - Recruiting
adult anaplastic astrocytoma; adult anaplastic oligodendroglioma; adult brain stem glioma; adult brain tumor; adult glioblastoma; Mixed Gliomas
- Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
ClinicalTrials.gov Identifier: NCT00083694 - Completed
Leukemia
- DCEP in Combination with Thalidomide as Salvage Therapy for Post Transplantation Relapse
ClinicalTrials.gov Identifier: NCT00083681 - Completed
Multiple Myeloma
- Treatment of Prostate Cancer with Docetaxel Alone and in Combination with Thalidomide
ClinicalTrials.gov Identifier: NCT00001942 - Completed
Prostatic Neoplasm
- Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
ClinicalTrials.gov Identifier: NCT00225290 - Recruiting
Carcinoma, Hepatocellular
- Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00432458 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00538733 - Recruiting
Multiple Myeloma
- Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
ClinicalTrials.gov Identifier: NCT00276705 - Recruiting
Liver Cancer
- Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
ClinicalTrials.gov Identifier: NCT00389935 - Recruiting
Arteriovenous Malformation; Hereditary Hemorrhagic Telangiectasia; Hematochezia; Melena
- Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00452569 - Recruiting
Multiple Myeloma
- A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
ClinicalTrials.gov Identifier: NCT00384800 - Recruiting
Carcinoma, Hepatocellular
- Use of Thalidomide in Patients With Arachnoiditis
ClinicalTrials.gov Identifier: NCT00284505 - Recruiting
Arachnoiditis
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00438841 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
Resources
- FDA Announces Approval of Drug for Hansen's DiseaseSide Effect; Imposes Unprecedented Authority to Restrict Distribution - Thalidomide Information (Center for Drug Evaluation and Research, FDA, OPHS, HHS)
- Frequently Asked Questions Concerning Thalidomide (Center for Drug Evaluation and Research, FDA, OPHS, HHS)
email this page
print this page
bookmark this page
feedback on this page
